English | Español
Patient Daily | May 7, 2023

Global Healthcare Exchange Completes Acquisition of Prodigo Solutions
Patient Daily | May 7, 2023

Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device
Patient Daily | May 7, 2023

New Data Demonstrates Indigo Aspiration System Improves ALI Patient Outcomes
Patient Daily | May 7, 2023

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Patient Daily | May 7, 2023

Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Patient Daily | May 7, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

Trending
+ Pharmaceuticals
Patient Daily | Sep 23, 2025

Wall Street Journal editorial board alleges hospitals misuse 340B program
+ Pharmaceuticals
Patient Daily | Sep 22, 2025

Nurses United for Healthcare Integrity says hospitals abuse 340B drug pricing program
+ Pharmaceuticals
Patient Daily | Sep 22, 2025

Staff Attorney of Legal Aid Society on 340B: 'Hospitals are exploiting the 340B program'
Patient Daily | Sep 19, 2025

ENT specialist on ongoing chronic sinus cases: ‘Some of it could be incomplete surgery’